Age-Related Macular Degeneration (AMD) affects millions worldwide, but the future is looking brighter thanks to Espansione Group's LightWave I clinical trial. 🚀 This first multicentric study focuses on patients with grade 2-3 AMD and employs photobiomodulation (Light Modulation® Low-Level Light Therapy (LM® LLLT)) to slow disease progression. Dr. Claudio Iovino and Dr. Enrico Borrelli, two of our esteemed investigators, are excited about the potential impact on patient care and healthcare economics. Discover the astonishing results of this groundbreaking research here: https://lnkd.in/dVENsjUM #espansionegroup #scienceonward #dryamd #geographicatrophy #photobiomodulation #PBM
